ID: ALA4098324

Max Phase: Preclinical

Molecular Formula: C29H22BrCl2N5O2S

Molecular Weight: 655.41

Molecule Type: Small molecule

Representations

Canonical SMILES:  N/C(=N/C(=N\S(=O)(=O)c1ccc(Cl)cc1)N1CC(c2ccccc2)C(c2ccc(Cl)cc2)=N1)c1ccc(Br)cc1

Standard InChI:  InChI=1S/C29H22BrCl2N5O2S/c30-22-10-6-21(7-11-22)28(33)34-29(36-40(38,39)25-16-14-24(32)15-17-25)37-18-26(19-4-2-1-3-5-19)27(35-37)20-8-12-23(31)13-9-20/h1-17,26H,18H2,(H2,33,34,36)

Standard InChI Key:  ZGMVKWSJIKNYTR-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 655.41

Molecular Weight (Monoisotopic): 653.0055

AlogP: 6.71

#Rotatable Bonds: 5

Polar Surface Area: 100.48

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 6.46

CX LogP: 7.12

CX LogD: 7.07

Aromatic Rings: 4

Heavy Atoms: 40

QED Weighted: 0.19

Np Likeness Score: -0.93

References

1. Iyer MR, Cinar R, Katz A, Gao M, Erdelyi K, Jourdan T, Coffey NJ, Pacher P, Kunos G..  (2017)  Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis.,  60  (3): [PMID:28085283] [10.1021/acs.jmedchem.6b01504]

Source

Source(1):

• Scientific Literature